Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
LSD
amphetamine Hallucinogen |
| gptkbp:actsOn |
5-HT2A receptor agonist
|
| gptkbp:CASNumber |
1354631-77-6
|
| gptkbp:category |
recreational drug
|
| gptkbp:chemicalFormula |
C18H23NO3
|
| gptkbp:discoveredBy |
gptkb:Ralf_Heim
|
| gptkbp:firstSynthesized |
2003
|
| gptkbp:hasStreet |
Dime-NBOMe
NBOMe-2C-D NBOMe-D |
| https://www.w3.org/2000/01/rdf-schema#label |
25D-NBOMe
|
| gptkbp:IUPACName |
2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine
|
| gptkbp:legalStatus |
gptkb:Class_A_(UK)
Schedule I (Canada) Schedule I (USA) NpSG (Germany) |
| gptkbp:molecularWeight |
301.38 g/mol
|
| gptkbp:relatedTo |
gptkb:25I-NBOMe
gptkb:2C-D |
| gptkbp:routeOfAdministration |
oral
sublingual buccal |
| gptkbp:sideEffect |
confusion
hypertension seizures tachycardia hallucinations agitation death (in overdose) vasoconstriction |
| gptkbp:usedFor |
recreational drug
|
| gptkbp:bfsParent |
gptkb:NBOMe_series
|
| gptkbp:bfsLayer |
7
|